Nardon, Chiara
Nardon, Chiara
DIPARTIMENTO DI BIOTECNOLOGIE
20S proteasome inhibition by gold(III)-based antitumor agents: from in vitro and in vivo studies to X-ray crystallography
2015-01-01 Nardon, C.; Cendron, L.; Dou, Q. P.; Beck, P.; Groll, M.; Zanotti, G.; Fregona, D.
A new strategy in chemotherapy: preliminary studies on Cu(II) complexes aimed at exploiting the enhanced copper uptake in malignancies
2012-01-01 Adami, A.; Dalla Via, L.; Imberti, C.; Nardon, C.; Marchiò, L.; Di Noto, V.; Fregona, D.
An excellence in medicinal inorganic chemistry: a portrait of the gold(I/III) complexes patented for therapeutic purposes from 2010 to 2015
2015-01-01 Pettenuzzo, N.; Brustolin, L.; Nardon, C.; Fregona, D.
Biological studies on Au(III) peptidomimetics about to enter Phase I clinical trials
2012-01-01 Nardon, C.; Ronconi, L.; Boscutti, G.; Paolini, M.; Formaggio, F.; Fregona, D.
CCK8 receptor-mediated cancer treatment strategies in target therapy
2013-01-01 Nardon, Chiara; A., Accardo; Boscutti, Giulia; DI NOTO, Vito; DALLA VIA, Lisa; Fregona, Dolores; G., Morelli
Copper(II)- and Ruthenium(III)-based complexes with promising anticancer activity
2013-01-01 Nardon, C.; Adami, A.; Boscutti, G.; Marchiò, L.; Dalla Via, L.; Fregona, D.
Cutting-edge anticancer agents: gold-based peptidomimetics targeting peptide transporters
2013-01-01 Nardon, Chiara; Q. P., Dou; Fregona, Dolores
Design and Development of new metal-based biosensors for the early detection of cancer antigens in oncology
2010-01-01 Nardon, C.; Fregona, D.
DESIGN AND DEVELOPMENT OF NEW METAL-BASED BIOSENSORS FOR THE EARLY DETECTION OF CANCER ANTIGENS IN ONCOLOGY
2009-01-01 Nardon, C.; Fregona, D.
Design and development of new metal-based biosensors for the early detection of cancer antigens in oncology
2009-01-01 Nardon, C.; Ronconi, L.; Sitran, S.; Favaro, M.; Fregona, D.
From cisplatin to world-shattering gold(III) anticancer agents
2011-01-01 Ronconi, L.; Boscutti, G.; Nagy, E. M.; Nardon, C.; Jirillo, A.; Fregona, D.
Gold(III) dithiocarbamate complexes induce cell death triggered by thioredoxin redox system inhibition, mitochondrial permeability increase, and activation of ERK pathway
2007-01-01 Giovagnini, L.; Nardon, C.; Saggioro, D.; Rigobello, M. P.; Paloschi, L.; Folda, A.; Ronconi, L.; Fregona, D.; Bindoli, A.
Gold-based peptidomimetics for a targeted anticancer therapy
2011-01-01 Boscutti, G.; Nardon, C.; Ronconi, L.; Trevisan, A.; Formaggio, F.; Dou, Q. P.; DALLA VIA, L.; Fregona, D.
In vitro and in vivo anticancer activity of recently patented gold-based peptidomimetics targeting peptide transporters
2012-01-01 Nardon, Chiara; Ping Dou, Q.; Fregona, Dolores
Leading-edge gold(III) targeted chemotherapeutics in translational oncology
2015-01-01 Nardon, Chiara; Fregona, Dolores
Metal-based dithiocarbamato anticancer agents: an overview
2008-01-01 Nardon, C.; Giovagnini, L.; Ronconi, L.; Fregona, D.
New insights into the mechanism of action of the gold(III) dithiocarbamato complex AuL12: upstream inhibition of the ubiquitin-proteasome pathway and encapsulation in natural polysaccharides
2015-01-01 Tomasello, M. F.; Nardon, C.; Lanza, V.; Di Natale, G.; Salmaso, S.; Milardi, D.; Caliceti, P.; Fregona, D.; Pappalardo, G.
New lanthanide-based biosensors for the early detection of cancer antigens
2010-01-01 Nardon, C.; D., Fregona
New metal-based cancer-targeting chemotherapeutics
2015-01-01 Nardon, Chiara; Fregona, Dolores
Novel inorganic chemotherapeutics for cancer treatment
2015-01-01 Nardon, C.; Pettenuzzo, N.; Paro, M.; Fregona, D.